Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Dare Bioscience

09/05/2025 22:23

Dare Bioscience Inc DARE.OQ DARE.O is expected to show a rise in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

The San Diego California-based  company is expected to report a 3,233.3% increase in revenue to $300 thousand from $9 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 58 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00​, above​ its last closing price of $2.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.53
-0.65
Missed
-21.9
Sep. 30 2024
-0.76
-0.73
-0.55
Beat
25
Jun. 30 2024
-0.65
0.00
1.52
Beat
​
Mar. 31 2024
-0.72
-0.72
-0.84
Missed
-16.7
​​Dec. 31 2023
-1.60
-1.18
-0.72
Beat
38.8
Sep. 30 2023
-1.16
-1.18
-1.08
Beat
8.2​
Jun. 30 2023
-1.21
-1.18
-1.20
Missed
-1.7
Mar. 31 2023
-1.22
-1.20
-1.08
Beat
10

This summary was machine generated May 9 at 21:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)